StreetInsider.com News Articles

Satellos forms scientific advisory board for aging and neuroscience

Tue, 27 Oct 2026 07:00:15 -0400

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) announced the formation of a Scientific Advisory Board comprised of six scientists with expertise in stem cell biology, regenerative medicine, neuroscience and small molecule chemistry.

The board will advise the Toronto-based clinical-stage company on emerging discoveries in stem cell biology, molecular signaling and disease pathology, including how aging influences regenerative capacity and how mechanisms governing stem cell behavior may relate to neurodegenerative disease.

Janet Rossant, Chief of Research Emeritus and Senior Scientist Emeritus at The Hospital for Sick Children, will chair the board. Other members include Rima Al-awar of New York University Abu Dhabi; Sebastian

Form 6-K Satellos Bioscience Inc. For: Oct 27

Tue, 27 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261027/27236492.html

Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience

Tue, 27 Oct 2026 07:00:00 -0400

Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry

TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of internationally recognized leaders in stem cell biology, regenerative medicine, neuroscience and small molecule chemistry who will help guide the company's long-term scientific exploration of regeneration, aging and neurodegenerative biology.

“Much of my scientific career has been devoted to understanding how cellular

Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience

Tue, 27 Oct 2026 07:00:00 -0400

Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry

“Much of my scientific career has been devoted to understanding how cellular

Form 6-K Satellos Bioscience Inc. For: Oct 21

Wed, 21 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261021/27212850.html

Satellos to Participate in Upcoming Investor Conferences

Wed, 21 Oct 2026 07:00:00 -0400

TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in November.

Guggenheim 3rd Annual Healthcare Innovation Conference
Date: Monday, Nov. 9, 2026
Fireside Chat: 9:30 a.m. ET
Location: Boston, MA
Webcast

Jefferies Global Healthcare Conference
Date: Nov. 18-19, 2026
Location: London, United Kingdom

Members of the Satellos leadership team will be available for one-on-one investor meetings during both conferences. A

Satellos to Participate in Upcoming Investor Conferences

Wed, 21 Oct 2026 07:00:00 -0400

Guggenheim 3rd Annual Healthcare Innovation Conference
Date: Monday, Nov. 9, 2026
Fireside Chat: 9:30 a.m. ET
Location: Boston, MA
Webcast

Jefferies Global Healthcare Conference
Date: Nov. 18-19, 2026
Location: London, United Kingdom

Members of the Satellos leadership team will be available for one-on-one investor meetings during both conferences. A

Satellos receives U.S. patent for forazapadin, valid until 2044

Mon, 05 Oct 2026 07:02:31 -0400

Satellos Bioscience Inc. (NASDAQ: MSLE) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, a composition of matter patent covering forazapadin, the company's lead drug candidate, as well as a broader class of AAK1 inhibitors and related compounds.

The patent, entitled "AP2 associated kinase 1 inhibitors and uses thereof," provides intellectual property protection through Sept. 6, 2044. Satellos said it may also be eligible for a Patent Term Extension following potential future U.S. marketing approval, which could extend protection beyond that date.

Frank Gleeson, co-founder and chief executive officer of Satellos, said the patent "reinforces the

Satellos Granted Composition of Matter Patent for Forazapadin

Mon, 05 Oct 2026 07:00:00 -0400

Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled “AP2 associated kinase 1 inhibitors and uses thereof.” The patent includes composition of matter claims covering forazapadin, Satellos’ lead clinical-stage drug candidate, as well as a broader class of AAK1 inhibitors and related compounds within the

Satellos Granted Composition of Matter Patent for Forazapadin

Mon, 05 Oct 2026 07:00:00 -0400

Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development

Form 6-K Satellos Bioscience Inc. For: Oct 05

Mon, 05 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261005/27145433.html

Satellos completes enrollment in Phase 2 DMD trial, data due Q1 2027

Wed, 30 Sep 2026 07:00:29 -0400

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) announced it has completed enrollment in BASECAMP, its Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD), with topline data now expected in the first quarter of 2027.

The trial enrolled ambulatory boys aged 7 to 10 across 18 clinical sites in the U.S., Canada, Australia, Belgium, Spain, Poland and Serbia. Participants were randomized 1:1:1 to receive forazapadin 60 mg, forazapadin 120 mg or placebo. The study includes a 12-week placebo-controlled period followed by a 36-week randomized active-treatment period. Primary endpoints include safety, tolerability and the effect of forazapadin

Form 6-K Satellos Bioscience Inc. For: Sep 30

Wed, 30 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260930/27125082.html

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Wed, 30 Sep 2026 07:00:00 -0400

Data from BASECAMP expected in Q1 2027

TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory boys 7 to 10 years of age. Forazapadin is an orally administered, small molecule drug candidate designed to restore muscle regeneration in people living with DMD, facioscapulohumeral muscular dystrophy (FSHD) and potentially other degenerative muscle diseases.

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Wed, 30 Sep 2026 07:00:00 -0400

Data from BASECAMP expected in Q1 2027

Satellos stock jumps after FDA clears FSHD trial for forazapadin

Thu, 24 Sep 2026 09:31:58 -0400

Investing.com -- Satellos Bioscience Inc (NASDAQ:MSLE) shares rose 6.8% in premarket trading Thursday after the company announced the U.S. Food and Drug Administration cleared its Investigational New Drug application for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD).

The FDA clearance expands development of forazapadin into a second degenerative muscle disease. Satellos plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026.

The company also announced that the FSHD Canada Foundation agreed to provide up to $5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD.

Satellos stock jumps after FDA clears FSHD trial for forazapadin

Thu, 24 Sep 2026 09:31:58 -0400

The FDA clearance expands development of forazapadin into a second degenerative muscle disease. Satellos plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026.

The company also announced that the FSHD Canada Foundation agreed to provide up to $5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD.

Satellos stock jumps after FDA clears FSHD trial for forazapadin

Thu, 24 Sep 2026 09:31:58 -0400

The FDA clearance expands development of forazapadin into a second degenerative muscle disease. Satellos plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026.

The company also announced that the FSHD Canada Foundation agreed to provide up to $5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD.

Satellos stock jumps after FDA clears FSHD trial for forazapadin

Thu, 24 Sep 2026 09:31:58 -0400

The FDA clearance expands development of forazapadin into a second degenerative muscle disease. Satellos plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026.

The company also announced that the FSHD Canada Foundation agreed to provide up to $5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD.

Satellos wins FDA clearance for forazapadin in second muscle disease

Thu, 24 Sep 2026 07:01:55 -0400

Satellos Bioscience Inc. (NASDAQ: MSLE) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for forazapadin in the treatment of facioscapulohumeral muscular dystrophy (FSHD), according to a company statement.

The Toronto-based clinical-stage company plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026. The study is designed as a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics, and potential efficacy of orally administered forazapadin at 60 mg and 120 mg doses in adults aged 18 and older with FSHD.

Satellos also announced a financing agreement with the FSHD Canada

Satellos wins FDA clearance for forazapadin in second muscle disease

Thu, 24 Sep 2026 07:01:55 -0400

Satellos also announced a financing agreement with the FSHD Canada

Satellos wins FDA clearance for forazapadin in second muscle disease

Thu, 24 Sep 2026 07:01:55 -0400

Satellos also announced a financing agreement with the FSHD Canada

Form 6-K Satellos Bioscience Inc. For: Sep 24

Thu, 24 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260924/27098701.html

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to S

Thu, 24 Sep 2026 07:00:00 -0400

FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical need
FSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD
Phase 2 study in FSHD expected to begin in Q4 2026

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to S

Thu, 24 Sep 2026 07:00:00 -0400

FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical need
FSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD
Phase 2 study in FSHD expected to begin in Q4 2026